{"id":"pegyinterferon-alfa-2a","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-30","effect":"Depression/mood changes"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"10-15","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1201560","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of interferon-alfa-2a conjugated to polyethylene glycol (PEG), which extends its half-life and reduces immunogenicity. It binds to interferon-alfa receptors on cell surfaces, triggering JAK-STAT signaling pathways that induce antiviral and antiproliferative gene expression. This mechanism makes it effective against chronic viral infections and certain malignancies.","oneSentence":"Pegyinterferon-alfa-2a is a pegylated form of interferon-alfa that activates innate immune responses to suppress viral replication and inhibit cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:10.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"},{"name":"Certain hematologic malignancies"}]},"trialDetails":[{"nctId":"NCT02068365","phase":"PHASE4","title":"An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2013-06","conditions":"Chronic Hepaititis B","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pegyinterferon-alfa-2a","genericName":"Pegyinterferon-alfa-2a","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegyinterferon-alfa-2a is a pegylated form of interferon-alfa that activates innate immune responses to suppress viral replication and inhibit cell proliferation. Used for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}